** J.P. Morgan upgrades gene therapy maker bluebird bio BLUE.O to "neutral" from "underweight" rating, citing co's announcement that it would be taken private
** Brokerage expects co's privatization to take place within 1H25
** BLUE says it will be taken private by Carlyle CG.O and SK Capital Partners
** 1 of 8 brokerages rate BLUE stock "buy", 7 "hold"; their median PT is $10 - LSEG data
** As of last close, stock down ~51.1% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.